ArticleKidney international2013
Serum aminoacylase-1 is a novel biomarker with potential prognostic utility for long-term outcome in patients with delayed graft function following renal transplantation.
Article in Kidney international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 49 citations in OpenAlex.
- Biomarker Prediction of Delayed Graft Function and Prognosis Post-Kidney Transplantation.Kidney international reports · 2026Article
- Future of non-invasive graft evaluation: A systematic review of proteomics in kidney transplantation.World journal of transplantation · 2025Review
- MiR-1271-5p promotes the growth and migration of neuroblastoma cells by regulating ACY-1.Translational cancer research · 2024Article
- Multi-omics Approach in Kidney Transplant: Lessons Learned from COVID-19 Pandemic.Current transplantation reports · 2023Article
- Mass spectrometry-based proteomics for advancing solid organ transplantation research.Frontiers in transplantation · 2023Review
- Article
- Effect of the ACY-1 gene on HER2 and TRAIL expression in rectal carcinoma.Experimental and therapeutic medicine · 2021Article
- Article
- Label-Free Quantitative Proteomics Identifies Novel Plasma Biomarkers for Distinguishing Pulmonary Tuberculosis and Latent Infection.Frontiers in microbiology · 2018Article
- Study of the expression and function of ACY1 in patients with colorectal cancer.Oncology letters · 2017Article
- A modified FASP protocol for high-throughput preparation of protein samples for mass spectrometry.PloS one · 2017Article
- Biomarkers in Transplantation--Proteomics and Metabolomics.Therapeutic drug monitoring · 2016Review
- Article
- iTRAQ-based quantitative proteomic analysis of longissimus muscle from growing pigs with dietary supplementation of non-starch polysaccharide enzymes.Journal of Zhejiang University. Science. B · 2015Article
- Higher Serum Angiotensinogen Is an Indicator of IgA Vasculitis with Nephritis Revealed by Comparative Proteomes Analysis.PloS one · 2015Article
- Through a glass darkly: seeking clarity in preventing late kidney transplant failure.Journal of the American Society of Nephrology : JASN · 2015Review
- Urine sample preparation in 96-well filter plates for quantitative clinical proteomics.Analytical chemistry · 2014Article
- Karyopherins: potential biological elements involved in the delayed graft function in renal transplant recipients.BMC medical genomics · 2014Article
- Biomarkers for renal transplantation: where are we?International journal of nephrology and renovascular disease · 2013Review
Corrections and comments
- Commented on by
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
Early identification and prognostic stratification of delayed graft function following renal transplantation has significant potential to improve outcome. Mass spectrometry analysis of serum samples, before and on day 2 post transplant from five patients with delayed graft function and five with an uncomplicated transplant, identified aminoacylase-1 (ACY-1) as a potential outcome biomarker. Following assay development, analysis of longitudinal samples from an initial validation cohort of 55 patients confirmed that the ACY-1 level on day 1 or 2 was a moderate predictor of delayed graft function, similar to serum creatinine, complementing the strongest predictor cystatin C. A further validation cohort of 194 patients confirmed this association with area under ROC curves (95% CI) for day 1 serum (138 patients) of 0.74 (0.67-0.85) for ACY-1, 0.9 (0.84-0.95) for cystatin C, and 0.93 (0.88-0.97) for both combined. Significant differences in serum ACY-1 levels were apparent between delayed, slow, and immediate graft function. Analysis of long-term follow-up for 54 patients with delayed graft function showed a highly significant association between day 1 or 3 serum ACY-1 and dialysis-free survival, mainly associated with the donor-brain-dead transplant type. Thus, proteomic analysis provides novel insights into the potential clinical utility of serum ACY-1 levels immediately post transplantation, enabling subdivision of patients with delayed graft function in terms of long-term outcome. Our study requires independent confirmation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.